Influence of ferromagnetic nanocomposite (Ferroplat) on human breast cancer cells of different malignancy degrees: pro/antioxidant balance and energy metabolism


  • V.F. Chekhun R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • I.N. Todor R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • N.Yu. Lukianova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • D.M. Horbyk R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • Yu.V. Lozovskaya R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • A.P. Burlaka R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • T.V. Borikun R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology


breast cancer, cardiolipin, energy metabolism, Ferroplat, glycolysis, malignancy degree, mitochondria, pro/antioxidant balance, reactive oxygen species, resistance


Summary. Aim: To study the effect of Ferroplat (FrP) on the indexes of pro/antioxidant balance and energy metabolism in breast cancer cells of different malignancy degree and different sensitivity to drug therapy. Materials and Methods: The study was carried out on breast cancer cells of low (T47D, MCF-7) and high malignancy degree (MCF-7/DDP (cisplatin-resistant), MDA-MB-231, MDA-MB-468) using cell culture techniques, immunocytochemical, biochemical, biophysical methods, flow cytometry and polarography. Results: We established that the addition of FrP to the culture medium reduces the activity of glucose-6-phosphate dehydrogenase (G6PDH), superoxide dismutase (SOD) and the level of non-protein thiols by 32–41% (p < 0.05). At the same time, there was an increase of the total level of ROS and the rate of NO generation by inducible NO synthase by 1.7–2.5 times (< 0.05). This testifies that FrP disturbs the antioxidant balance in cells, resulting in their death. Also, the use of FrP led to a decrease in the rate of oxygen absorption in MCF-7 and T47D cells by 26% and 25%, respectively (p < 0.05). In cells of high malignancy degree this index decreased by 38–40% under the influence of FrP. Incubation of MCF-7 and T47D cells with the indicated agent also reduced the content of phospholipid cardiolipin by 15–16% (p < 0.05), and in MDA-MB-231, MCF-7/DDP, MDA-MB-468 cells — by 29%, 30% and 32%, respectively. In addition, the effect of FrP caused a decrease in the levels of Mg2+ and lactate in MCF-7 and T47D cells by 21–29% and 14–24%, respectively, whereas in MDA-MB-231, MDA-MB-468, MCF-7/DDP cells — by 34–38% and 32–35%, respectively. In this case, the agent raised the level of glucose in the cells of low malignancy degree by 20–23% (p < 0.05), and in the cells of high malignancy degree and with the phenotype of drug resistance — by 31–36%. However, the nanocomposite did not affect the activity of lactate dehydrogenase in all studied breast cancer cells. Conclusion: The study has shown that FrP has an effect on the pro/antioxidant balance and energy metabolism of cancer cells. In addition, the denoted effect of FrP was more pronounced in the breast cancer cells with a high malignancy degree and the phenotype of drug resistance.


Chekhun VF, Shpilevaya SI. The role of endogenous iron in the formation of tumor sensitivity to antitumor therapy. Voprosy Onkologii 2010; 56: 251–61 (in Russian).

Terman A, Kurz T. Lysosomal iron, iron chelation, and cell death. Antioxid Redox Signal 2013; 18: 888–98.

Lamy PJ, Durigova A, Jacot W. Iron homeostasis and anemia markers in early breast cancer. Clin Chim Acta 2014; 434: 434–40.

Torti SV, Torti FM. Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog 2013; 18: 435–48.

Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci 2014; 19: 164–74.

Huang X, Fung ET, Yip C. Serum prohepcidin is associated with soluble transferrin receptor-1 but not ferritin in healthy post-menopausal women. Blood Cells Mol Dis 2008; 41: 265–9.

Hua MY, Yang HW, Chuang CK, et al. Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials 2010; 31: 7355–63.

Gutierrez E, Kovacevic Z, Saletta F. Iron chelators for the treatment of cancer. Curr Med Chem 2012; 19: 2689–702.

Gautier J, Munnier E, Paillard A. A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting. Int J Pharmacol 2012; 423: 16–25.

Kovacevic Z, Chikhani S, Lovejoy DB, et al. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol 2011; 80: 598–609.

Chekman IS, Doroshenko AM. Interaction of iron oxide nanoparticles with cell and components of biomembrane. Ukr Med Chasopys 2012; 1: 31–7 (in Ukrainian).

Orel VE, Grabovoy AN, Romanov AV. Mitochondria in Lewis lung carcinoma cells under the effect of magnetosensitive nanocomplex and radiofrequency hyperthermia. Bull Exp Biol Med 2013; 155: 484–7.

Liu M, Xue Z, Liu H, et al. Surface wetting in liquid-liquid-solid triphase systems: solid-phase-independent transition at the liquid-liquid interface by Lewis acid-base interactions. Angew Chem Int Educ Engl 2012; 51: 8348–51.

Li YJ, Dong M, Kong FM, et al. Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics. Int J Pharmacol 2015; 489: 83–90.

Chekhun VF. Nanotechnologies in oncology: perspectives for development and unforeseen difficulties. The Lancet Oncology, Ukrainian Edition 2010; 4: 2–3 (in Russian).

Prijic S, Sersa G. Magnetic nanoparticles as targeted delivery systems in oncology. Radiol Oncol 2011; 45: 1–16.

Zhang P, Sadler PJ. Redox‐active metal complexes for anticancer therapy. Eur J Inorg Chem 2017; 12: 1541–8.

Zhang C, Shi G, Zhang J, et al. Redox-and light-responsive alginate nanoparticles as effective drug carriers for combinational anticancer therapy. Nanoscale 2017; 9: 3304–14.

Chekhun VF, Mokhir A, Daum S, et al. Pharmacological effect of aminoferrocene in mice with L1210 leukemia. Exp Oncol 2015; 37: 120–5.

Chekhun VF, Zalutskii IV, Naleskina LA, et al. Modifying effects of lactoferrin in vitro on molecular phenotype of human breast cancer cells. Exp Oncol 2015; 37: 181–6.

Yalovenko TM, Todor IM, Lukianova NY, Chekhun VF. Hepcidin as a possible marker in determination of malignancy degree and sensitivity of breast cancer cells to cytostatic drugs. Exp Oncol 2016; 38: 84–8.

Chekhun VF, Lukianova NY, Borikun TV, et al. Artemisinin modulating effect on human breast cancer cell lines with different sensitivity to cytostatics. Exp Oncol 2017: 39: 25–9.

Zalutskii IV, Lukianova NY, Storchai DM, et al. Influence of exogenous lactoferrin on the oxidant/antioxidant balance and molecular profile of hormone receptor-positive and -negative human breast cancer cells in vitro. Exp Oncol 2017; 39: 106–11.

Ogura R, Ueta H, Sugiyama M, Hidaka T. Distribution of superoxide dismutase activity in the epidermis: measurement with electron spin resonance spin trapping. J Invest Dermatol 1990; 94: 227–9.

Gautheron DC. Mitochondrial oxidative phosphorylation and respiratory chain. J Inher Metabolic Dis 1984; 7: 57–61.

Gula NM, Margitich VM. The Fatty Acids and its Derivatives at Pathological States. Kyiv: Naukova Dumka, 2009. 334 p. (in Ukrainian).




How to Cite

Chekhun, V., Todor, I., Lukianova, N., Horbyk, D., Lozovskaya, Y., Burlaka, A., & Borikun, T. (2023). Influence of ferromagnetic nanocomposite (Ferroplat) on human breast cancer cells of different malignancy degrees: pro/antioxidant balance and energy metabolism. Experimental Oncology, 40(4), 268–274. Retrieved from



Original contributions

Most read articles by the same author(s)

1 2 3 > >>